{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:28:57Z","timestamp":1768397337160,"version":"3.49.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2007,2,28]],"date-time":"2007-02-28T00:00:00Z","timestamp":1172620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2007,6,27]]},"DOI":"10.1007\/s00198-007-0349-5","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T10:13:39Z","timestamp":1172571219000},"page":"1047-1061","source":"Crossref","is-referenced-by-count":81,"title":["Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial"],"prefix":"10.1007","volume":"18","author":[{"given":"O.","family":"Str\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Borgstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. S.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Haentjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Johnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,28]]},"reference":[{"issue":"Suppl 1","key":"349_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/8756-3282(93)90341-7","volume":"14","author":"LJ Melton 3rd","year":"1993","unstructured":"Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14(Suppl 1):S1\u2013S8","journal-title":"Bone"},{"issue":"11","key":"349_CR2","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, FIT Research Group et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85(11):4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"issue":"9041","key":"349_CR3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Fracture Intervention Trial Research Group et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535\u20131541","journal-title":"Lancet"},{"issue":"24","key":"349_CR4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. Jama 280(24):2077\u20132082","journal-title":"Jama"},{"issue":"5","key":"349_CR5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00019053-200321050-00002","volume":"21","author":"O Johnell","year":"2003","unstructured":"Johnell O et al (2003) Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305\u2013314","journal-title":"Pharmacoeconomics"},{"key":"349_CR6","unstructured":"Borgstr\u00f6m F et al (2003) Cost-effectiveness of alendronate for the treatment of postmenopausal women in the UK. submitted"},{"key":"349_CR7","unstructured":"Borgstr\u00f6m F et al (2003) Cost-Effectiveness of alnedronate in the treatment of male osteoporosis. Bone. accepted"},{"issue":"43","key":"349_CR8","first-page":"4112","volume":"165","author":"L Jonsson","year":"2003","unstructured":"Jonsson L, Borgstrom F, Zethraeus N (2003) [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial]. Ugeskr Laeger 165(43):4112\u20134116","journal-title":"Ugeskr Laeger"},{"issue":"5","key":"349_CR9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00019053-199814050-00007","volume":"14","author":"AJ Rosner","year":"1998","unstructured":"Rosner AJ et al (1998) Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14(5):559\u2013573","journal-title":"Pharmacoeconomics"},{"key":"349_CR10","unstructured":"Christensen PM, Brixen K, Kristiansen IS (2003) Danish osteoporosis outcome model (DOOM)"},{"issue":"1\u20132","key":"349_CR11","first-page":"36","volume":"100","author":"F Borgstrom","year":"2003","unstructured":"Borgstrom F, Zethraeus N (2003) [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. Lakartidningen 100(1\u20132):36-40","journal-title":"Lakartidningen"},{"key":"349_CR12","unstructured":"Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. [cited 2007-01-03]; Available from: http:\/\/www.nice.org.uk\/page.aspx?o=370643"},{"issue":"4","key":"349_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","volume":"103","author":"JL Stock","year":"1997","unstructured":"Stock JL et al (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103(4):291\u2013297","journal-title":"Am J Med"},{"issue":"11","key":"349_CR14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875\u2013883","journal-title":"Ann Intern Med"},{"issue":"9","key":"349_CR15","first-page":"3109","volume":"85","author":"RP Tonino","year":"2000","unstructured":"Tonino RP, Phase III Osteoporosis Treatment Study Group et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85(9):3109\u20133115","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"349_CR16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"12","key":"349_CR17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: Based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781\u20131793","journal-title":"Osteoporos Int"},{"key":"349_CR18","unstructured":"Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. (Belgium)"},{"issue":"2","key":"349_CR19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00198-004-1680-8","volume":"16","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16(2):134\u2013141","journal-title":"Osteoporos Int"},{"issue":"5","key":"349_CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01623349","volume":"4","author":"I Elffors","year":"1994","unstructured":"Elffors I et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4(5):253\u2013263","journal-title":"Osteoporos Int"},{"issue":"5","key":"349_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S8756-3282(01)00603-2","volume":"29","author":"CM Lofthus","year":"2001","unstructured":"Lofthus CM et al (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29(5):413\u2013418","journal-title":"Bone"},{"issue":"8","key":"349_CR22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA et al (2000) Long-term risk of osteoporotic fracture in Malm\u00f6. Osteoporos Int 11(8):669\u2013674","journal-title":"Osteoporos Int"},{"issue":"2","key":"349_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1302\/0301-620X.80B2.7762","volume":"80","author":"BR Singer","year":"1998","unstructured":"Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243\u2013248","journal-title":"J Bone Joint Surg Br"},{"issue":"4","key":"349_CR24","first-page":"93","volume":"23","author":"JG Brecht","year":"2003","unstructured":"Brecht JG et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23(4):93\u2013105","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"349_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004173","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA et al (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120\u2013127","journal-title":"Osteoporos Int"},{"issue":"11","key":"349_CR26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00198-004-1643-0","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA et al (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862\u2013871","journal-title":"Osteoporos Int"},{"issue":"7041","key":"349_CR27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254\u20131259","journal-title":"Br Med J"},{"issue":"5","key":"349_CR28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468\u2013489","journal-title":"Osteoporos Int"},{"issue":"4","key":"349_CR29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u2013739","journal-title":"J Bone Miner Res"},{"issue":"2","key":"349_CR30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375\u2013382","journal-title":"Bone"},{"issue":"4","key":"349_CR31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1359\/jbmr.2002.17.4.716","volume":"17","author":"D Felsenberg","year":"2002","unstructured":"Felsenberg D et al (2002) Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17(4):716\u2013724","journal-title":"J Bone Miner Res"},{"key":"349_CR32","unstructured":"Report on osteoporosis in the European community-action for prevention. 1998, European Commission-Employment & Social Affairs"},{"issue":"1","key":"349_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1099-1050(199802)7:1<31::AID-HEC316>3.0.CO;2-7","volume":"7","author":"N Zethraeus","year":"1998","unstructured":"Zethraeus N (1998) Willingness to pay for hormone replacement therapy. Health Econ 7(1):31\u201338","journal-title":"Health Econ"},{"key":"349_CR34","unstructured":"Life tables, years 1999\u20132001. Institut National d\u2019\u00c9dutes d\u00e9mographiques. 2004"},{"key":"349_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4757-6822-0_1","volume":"4","author":"M Johannesson","year":"1996","unstructured":"Johannesson M (1996) Theory and methods of economic evaluation of health care. Dev Health Econ Public Policy 4:1\u2013245","journal-title":"Dev Health Econ Public Policy"},{"issue":"6","key":"349_CR36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","volume":"38","author":"TO Tengs","year":"2000","unstructured":"Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583\u2013637","journal-title":"Med Care"},{"key":"349_CR37","unstructured":"Statistics Norway http:\/\/www.ssb.no\/ ). 2004"},{"issue":"5","key":"349_CR38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1742-7843.2005.pto_08.x","volume":"96","author":"PM Christensen","year":"2005","unstructured":"Christensen PM et al (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387\u2013396","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"349_CR39","unstructured":"Statistics Sweden. Sweden\u00b4s Statistical Databases. http:\/\/www.scb.se\/eng\/databaser\/ssd.asp"},{"key":"349_CR40","unstructured":"Interim Life Tables. 2002 [cited http:\/\/www.gad.gov.uk\/policy_and_stats\/life_tables.htm"},{"issue":"6","key":"349_CR41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s001980050105","volume":"8","author":"A Oden","year":"1998","unstructured":"Oden A et al (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599\u2013603","journal-title":"Osteoporos Int"},{"key":"349_CR42","doi-asserted-by":"crossref","unstructured":"Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468\u2013473","DOI":"10.1016\/S8756-3282(03)00061-9"},{"issue":"6","key":"349_CR43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","volume":"105","author":"MJ Parker","year":"1991","unstructured":"Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443\u2013446","journal-title":"Public Health"},{"key":"349_CR44","unstructured":"Kanis J et al (2002) Excess mortality after vertebral fracture. WHO Collabortaing centre for metabolic bone diseases: Sheffield, UK"},{"key":"349_CR45","unstructured":"ISPOR, Pharmacoeconomic guidelines. 2005, http:\/\/www.ispor.org\/PEguidelines\/index.asp"},{"key":"349_CR46","unstructured":"TIPOS DE INTER\u00c9S, BANCO DE ESPA\u00d1A\/ESTAD\u00cdSTICAS COMPLEMENTARIAS. http:\/\/www.bde.es\/ , 2005"},{"issue":"1","key":"349_CR47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/17453679709003968","volume":"68","author":"N Zethraeus","year":"1997","unstructured":"Zethraeus N et al (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13\u201317","journal-title":"Acta Orthop Scand"},{"key":"349_CR48","unstructured":"Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a swedish survey. Working Paper Series in Economics and Finance, 512"},{"key":"349_CR49","unstructured":"OECD Health Data 2003-A comparative analysis of 30 countries. 2003 [cited; Available from: www.oecd.org\/health\/healthdata"},{"key":"349_CR50","unstructured":"World development indicators-relative prices and exchange rates. 2004 [cited 2004; Available from: http:\/\/siteresources.worldbank.org\/ICPINT\/Resources\/Table5_7.pdf"},{"issue":"5","key":"349_CR51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417\u2013427","journal-title":"Osteoporos Int"},{"key":"349_CR52","unstructured":"Zethraeus N Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Poster at ECCEO, Vienna"},{"key":"349_CR53","doi-asserted-by":"crossref","unstructured":"J\u00f6nsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30\u201338","DOI":"10.3109\/03009749609103742"},{"issue":"7133","key":"349_CR54","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736\u2013741","journal-title":"Br Med J"},{"issue":"3","key":"349_CR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurpub\/9.3.211","volume":"9","author":"L Lundberg","year":"1999","unstructured":"Lundberg L et al (1999) Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 9(3):211\u2013217","journal-title":"Eur J Public Health"},{"issue":"1","key":"349_CR56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20\u201326","journal-title":"Osteoporos Int"},{"issue":"10","key":"349_CR57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s001980200107","volume":"13","author":"JE Brazier","year":"2002","unstructured":"Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768\u2013776","journal-title":"Osteoporos Int"},{"issue":"7324","key":"349_CR58","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/bmj.323.7324.1300","volume":"323","author":"J Raftery","year":"2001","unstructured":"Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323(7324):1300\u20131303","journal-title":"Br Med J"},{"key":"349_CR59","unstructured":"\u00d6versyn av samh\u00e4llsekonomiska metoder och kalkylv\u00e4rden p\u00e5 transportomr\u00e5det-ASEK Review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport, 2002. 4"},{"issue":"10","key":"349_CR60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s001980200106","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, J\u00f6nsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13(10):765\u2013767","journal-title":"Osteoporos Int"},{"key":"349_CR61","unstructured":"Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health, W.C.o.M.a. Health, Editor. 2001:Geneva"},{"issue":"3","key":"349_CR62","first-page":"97","volume":"11","author":"WM Hart","year":"2002","unstructured":"Hart WM et al (2002) An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la osteoporosis postmenop\u00e1usica con risedronato o alendronato. REEMO 11(3):97\u2013104","journal-title":"REEMO"},{"issue":"5","key":"349_CR63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s001980070102","volume":"11","author":"P Autier","year":"2000","unstructured":"Autier P, Belgian Hip Fracture Study Group et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int 11(5):373\u2013380","journal-title":"Osteoporos Int"},{"issue":"4","key":"349_CR64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01623384","volume":"6","author":"A Ankjaer-Jensen","year":"1996","unstructured":"Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6(4):265\u2013275","journal-title":"Osteoporos Int"},{"issue":"3","key":"349_CR65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-5122(96)01099-7","volume":"26","author":"P Visentin","year":"1997","unstructured":"Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26(3):185\u2013192","journal-title":"Maturitas"},{"key":"349_CR66","unstructured":"Andersen L et al (1995) Cost-effectiveness of alendronate for the prevention of osteoporotic fractures in Norwegian women. Statens Institutt for Folkhelse: Oslo"},{"issue":"6","key":"349_CR67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s001980050107","volume":"8","author":"P Dolan","year":"1998","unstructured":"Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8(6):611\u2013617","journal-title":"Osteoporos Int"},{"key":"349_CR68","unstructured":"Kanis JA (2002) Epidemiology and costs of fractures in the UK: Background document for male osteoporosis model. Personal communication"},{"key":"349_CR69","unstructured":"Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a Swedish survey. Working paper series in economics and finance, 512. Stockholm: Stockholm School of Economics"},{"issue":"2","key":"349_CR70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bone.2004.03.035","volume":"35","author":"S Puffer","year":"2004","unstructured":"Puffer S et al (2004) Health care costs of women with symptomatic vertebral fractures. Bone 35(2):383\u2013386","journal-title":"Bone"},{"key":"349_CR71","unstructured":"Local Government in Denmark. http:\/\/www.kl.dk\/240830"},{"key":"349_CR72","unstructured":"1. Stockholms stads budgetavr\u00e4kning. Stadsledningskontorets redovisningsstab 2003 [cited]"},{"key":"349_CR73","unstructured":"Netten A, Rees T, Harrison G (2002) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http:\/\/www.ukc.ac.uk\/PSSRU\/"},{"key":"349_CR74","unstructured":"System BSS Belgian Social Security System. [cited 2005-07-02]; Available from: http:\/\/www.riziv.be\/insurer\/fr\/rate\/pdf\/2004\/doctors\/raad-20041001-fr.pdf"},{"key":"349_CR75","unstructured":"The danish ministry of health. Takstsystem 2001, 2000. ISBN 1395\u20132528"},{"key":"349_CR76","unstructured":"AMeli, L\u2019Assurance Maladie en Ligne 2004 [cited; Available from: http:\/\/www.ameli.fr"},{"key":"349_CR77","unstructured":"EBM 2000 plus. 2004, Kassen\u00e4rztliche Vereinigung Bayern"},{"key":"349_CR78","unstructured":"Medi 3 (internet reference,Norwegian private healthcare). 2005 [cited; Available from: http:\/\/www.medi3.no"},{"issue":"13","key":"349_CR79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00019053-200422130-00006","volume":"22","author":"J Honorato","year":"2004","unstructured":"Honorato J et al (2004) Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13):885\u2013894","journal-title":"Pharmacoeconomics"},{"key":"349_CR80","unstructured":"Curtis L, Netten A (2004) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http:\/\/www.ukc.ac.uk\/PSSRU\/"},{"key":"349_CR81","unstructured":"Osteoporosis in the European community: A call to action: an audit of policy developments since 1998, in international osteoporosis foundation. 2001"},{"key":"349_CR82","unstructured":"Priser f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen-V\u00e5rdtj\u00e4nster per klinik. 2003 Universitetssjukhuset i Lund"},{"key":"349_CR83","unstructured":"Stevenson M, Jones ML, Nigris Ed. Assessment report: The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis, http:\/\/www.nice.org . 2004 [cited"},{"key":"349_CR84","unstructured":"centre Belge d\u2019Information Pharmacoth\u00e9rapeutique, the Belgian Pharmacotherapeutic Information Centre. 2005 [cited; Available from: http:\/\/www.cbip.be\/GGR\/MPG\/MPG_NH.cfm#MP_2541"},{"key":"349_CR85","unstructured":"L\u00e6gemiddelkataloget (Denmark). 2004 [cited; Available from: http:\/\/www.lmk.dk"},{"key":"349_CR86","unstructured":"Vidal-pro (L\u2019information de r\u00e9f\u00e9rence sur le m\u00e9dicament). 2004 [cited; Available from: http:\/\/www.vidalpro.net"},{"key":"349_CR87","unstructured":"Ministero della salute, Italy. 2004 [cited; Available from: http:\/\/www.ministerosalute.it\/index.jsp"},{"key":"349_CR88","unstructured":"Felleskatalogen. 2004 [cited; Available from: http:\/\/www.felleskatalogen.no"},{"key":"349_CR89","unstructured":"Base de datos del medicamento. 2004 [cited; Available from: http:\/\/pfarmals.portalfarma.com:8080\/farma\/"},{"key":"349_CR90","unstructured":"FASS.se f\u00f6r F\u00f6rskrivare. [cited 2004-05-06]; Available from: http:\/\/www.fass.se"},{"key":"349_CR91","unstructured":"British National Formulary 2004"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0349-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-007-0349-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0349-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:00:49Z","timestamp":1558623649000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-007-0349-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,28]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,6,27]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s00198-007-0349-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,28]]}}}